Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APL 102

Next Previous
Drug Profile

APL 102

Alternative Names: APL-102; CBT 102

Latest Information Update: 29 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CBT Pharmaceuticals
  • Developer Apollomics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Colony-stimulating factor receptor antagonists; Discoidin domain receptor 1 antagonists; Mitogen-activated protein kinase inhibitors; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-ret inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 29 Jul 2025 APL 102 is still in phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule)
  • 03 Apr 2025 Apollomics terminates a phase-I clinical trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China (PO) due to adjustments in corporate development strategy (NCT05055518)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top